DYN at a glance
Dyne Therapeutics, Inc. (DYN, SEC CIK 1818794) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Dyne Therapeutics, Inc. (DYN) shares worth $931.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Kerr Douglas on November 13, 2026 of 2,604 shares at $16.82 per share.
- In the last 90 days, DYN insiders reported 1 open-market purchase ($40K) and 9 open-market sales ($422K) on Form 4, a net sale of $382K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 1 buy · 9 sells
- Net −$382K
- 13F holders
- 30 funds
- $931.6M · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development of product candidates for rare muscle diseases, leveraging manufacturing agreements with CMOs
- New master manufacturing services agreements in 2025 securing $169.9M total fees committed through 2027 for product candidate components
- Strategic emphasis on formalizing manufacturing capacity to support clinical and production scalability versus prior informal agreements
- Notable R&D investment: $31.2M paid towards non-current assets under manufacturing agreement as of Dec 31, 2025, with additional $109.5M committed
- Lease agreement for office and lab space with 8.5-year term started Sept 2021, with monthly rent increasing to $0.5M during term
Risk Factors
- FDA clinical hold on z-rostudirsen IND in Jan 2022, delaying trial start until July 2022 clearance
- Geopolitical and market risk from clinical and regulatory approval uncertainty in US and EU (FDA, EMA) regulatory agencies
- Supply chain vulnerability in establishing manufacturing for Fab antibody, linker, therapeutic payload components for clinical and commercial supply
- Competitive risk from delayed commercialization of product candidates until at least 2027, risking losing market share to established biotech peers
- Financial risk from $1.4B accumulated deficit with net losses of $446.2M in 2025 and $317.4M in 2024, reliant on $1.1B cash runway to Q1 2028 and $275M Hercules loan facility with restrictive covenants
Management Discussion & Analysis
- No profitability or margin figures provided, expenses expected to increase with ongoing activities
- No segment financial data; primary emphasis on research and development of multiple product candidates
- Cash, cash equivalents, marketable securities sufficient to fund operations into Q1 2028
- Capital needs to be met via equity, debt, collaborations, with risk of dilution and restrictive covenants; risk of delayed development if funding unmet
AI summary of the DYN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added regulatory risk, BIOSECURE Act restrictions could disrupt Chinese supplier relationships and increase manufacturing costs
- Most material update, DMD competition intensified after Avidity’s September 2026 priority review for delpacibart zotadirsen
- Clinical risk, FDA previously placed z-rostudirsen’s IND on hold pending additional clinical and non-clinical information
- Operational risk, reliance on single or limited suppliers for Fabs, linkers and payloads creates interruption exposure
- Financial risk, $1.134 billion liquidity expected to fund operations through second quarter 2028, subject to plan assumptions
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales since inception
- Net loss $193.6M vs $108.0M YoY, operating margin not meaningful due to zero revenue
- Best-performing program: z-rostudirsen R&D $66.9M vs $22.7M, worst: z-basivarsen $32.8M vs $37.9M
- Cash, equivalents and marketable securities $1.134B; operating cash use $452.7M vs $291.4M YoY
- July offering raised $404.9M; potential z-rostudirsen launch Q1 2027, cash runway into Q2 2028
AI summary of the DYN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- FDA priority review for z-rostudirsen, with PDUFA action date January 21, 2027, creates the near-term approval catalyst
- Cash, cash equivalents and marketable securities of $1.134 billion expected to fund operations into Q2 2028
Item EX-99.2: Item EX-99.2
- ACHIEVE MAD data supports z-basivarsen efficacy in DM1, with 12-month pooled-dose improvements across strength, mobility, and patient-reported outcomes
- Pooled group N=26 showed QMT total improvement 4.8 percentage points, hand grip improvement 4.8 percentage points, and 10MWR improvement 0.26 seconds
Item 7.01: Regulation FD Disclosure
- Dyne reported additional one-year Phase 1/2 ACHIEVE data for z-basivarsen in myotonic dystrophy type 1
- Data cover the multiple ascending dose portion, extending durability evidence beyond initial treatment results
Item EX-99.1: Item EX-99.1
- One-year Phase 1/2 data strengthen z-basivarsen’s efficacy case across myotonia, function, strength and patient-reported outcomes
- vHOT improved 3.2 seconds at 6 months versus 0.4-second worsening on placebo, a 3.6-second relative benefit
Item 8.01: Other Events
- One-year pooled ACHIEVE data showed sustained improvements in myotonia, function, strength and patient-reported outcomes
- vHOT improved 3.2 seconds at six months versus 0.4-second worsening for placebo, a 3.6-second relative improvement
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results covered quarter ended June 30, 2026
- Press release issued July 29, 2026 and furnished as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- FDA accepted z-rostudirsen’s DMD BLA with Priority Review; PDUFA action date January 21, 2027, supporting potential Q1 2027 launch
- ACHIEVE enrollment completed at 71 participants; topline z-basivarsen data planned Q1 2027, supporting potential accelerated-approval filing in Q3 2027
AI summaries of DYN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DYN
Don't miss the next DYN filing
- Alerts as it files. A push when DYN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DYN, by share count.
- Ask anything. An AI agent that reads every DYN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kerr Douglas | Sell | Nov 13, 2026 | 2,604 | $16.82 |
| Lucera Erick | Sell | Nov 13, 2026 | 1,991 | $16.82 |
| Cox John | Sell | Nov 13, 2026 | 5,513 | $16.82 |
| Friedl-Naderer Johanna | Sell | Nov 13, 2026 | 231 | $16.82 |
| Kerr Douglas | A | Oct 20, 2026 | 8,000 | - |
| Kerr Douglas | A | Oct 20, 2026 | 12,000 | - |
| Posner Brian S | Buy | Oct 2, 2026 | 2,500 | $16.00 |
| Cox John | Sell | Sep 8, 2026 | 5,658 | $18.88 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$242.2M | -$343.9M | -$468.2M |
| Net Income | - | -$317.4M | -$446.2M |
| Balance Sheet | |||
| Total Assets | $165.1M | $691.2M | $1.2B |
| Equity | $91.3M | $629.8M | $972.1M |
| ROE | - | -50.4% | -45.9% |
| Per Share | |||
| EPS | $-3.95 | $-3.37 | $-3.47 |
| Cash Flow | |||
| Operating CF | -$188.2M | -$292.4M | -$403.2M |
| CapEx | $729K | $2.4M | $1.9M |
Source: XBRL data in Dyne Therapeutics, Inc. (DYN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DYN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 30 | $931.6M |
| Q2 2026 | 31 | $1.40B |
| Q1 2026 | 29 | $980.6M |
| Q4 2025 | 23 | $1.00B |
| Q3 2025 | 25 | $634.8M |
| Q2 2025 | 24 | $359.6M |
| Q1 2025 | 22 | $289.2M |
| Q4 2024 | 18 | $577.3M |
- BlackRock+2.07M (+17%)
- Vanguard Capital Management LLC+1.24M (+20%)
- Citadel Advisors LLC+810.8K (+71%)
- State Street Corp+700.0K (+9%)
- Vanguard Portfolio Management LLC+643.2K (+16%)
- JPMorgan Chase & Co−238.7K (-8%)
- Renaissance Technologies LLC−228.9K (-63%)
- T. Rowe Price Group−210.9K (-5%)
- Ameriprise Financial−177.1K (-59%)
- Goldman Sachs Group−93.7K (-4%)
- Soros Fund Management+20.0K
- Principal Financial Group+15.6K
- FMR LLC (Fidelity)−11.21M
- Mangrove Partners−47.9K
- Blackstone Group−22.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DYN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 22, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 29, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DYN SEC filings: frequently asked questions
Are DYN insiders buying or selling?
In the last 90 days, Dyne Therapeutics, Inc. (DYN) officers, directors and 10% owners reported 1 open-market purchase worth $40,000 by 1 insider and 9 open-market sales worth $421,679 by 4 insiders on Form 4, a net sale of $381,679. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DYN stock?
As of September 30, 2026, the largest Dyne Therapeutics, Inc. (DYN) holders among the 13F filers tracked by SignalX were BlackRock ($233.1 million), State Street Corp ($131.4 million), Vanguard Capital Management LLC ($121.7 million), Vanguard Portfolio Management LLC ($75.6 million), T. Rowe Price Group ($60.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in DYN's latest 10-K?
In the 10-K filed March 2, 2026, Dyne Therapeutics, Inc. (DYN) flagged: FDA clinical hold on z-rostudirsen IND in Jan 2022, delaying trial start until July 2022 clearance. Geopolitical and market risk from clinical and regulatory approval uncertainty in US and EU (FDA, EMA) regulatory agencies. (AI summary of the Risk Factors section.)
What did DYN report in its latest 8-K?
Dyne Therapeutics, Inc. (DYN) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest DYN SEC filings?
Dyne Therapeutics, Inc. (DYN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 16, 2026.
What is DYN's SEC CIK number?
Dyne Therapeutics, Inc. (DYN)'s SEC Central Index Key (CIK) is 1818794. EDGAR lists every DYN filing under that number.
Ask anything about DYN
The research agent reads DYN's filings, financials, insider trades and 13F holders, then answers with sources.